Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant RC48 plus Carboplatin for HER2-expressing Advanced Ovarian Cancer
NCT06574763Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in ovarian cancer, sponsored by Sun Yat-sen University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06574763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574763.